Tags

Type your tag names separated by a space and hit enter

CKD-MBD: impact on management of kidney disease.
Clin Exp Nephrol. 2007 Dec; 11(4):261-268.CE

Abstract

Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.

Authors+Show Affiliations

Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan. ogatah@med.showa-u.ac.jp.Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan.Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18085385

Citation

Ogata, Hiroaki, et al. "CKD-MBD: Impact On Management of Kidney Disease." Clinical and Experimental Nephrology, vol. 11, no. 4, 2007, pp. 261-268.
Ogata H, Koiwa F, Kinugasa E, et al. CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol. 2007;11(4):261-268.
Ogata, H., Koiwa, F., Kinugasa, E., & Akizawa, T. (2007). CKD-MBD: impact on management of kidney disease. Clinical and Experimental Nephrology, 11(4), 261-268. https://doi.org/10.1007/s10157-007-0492-5
Ogata H, et al. CKD-MBD: Impact On Management of Kidney Disease. Clin Exp Nephrol. 2007;11(4):261-268. PubMed PMID: 18085385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CKD-MBD: impact on management of kidney disease. AU - Ogata,Hiroaki, AU - Koiwa,Fumihiko, AU - Kinugasa,Eriko, AU - Akizawa,Tadao, Y1 - 2007/12/21/ PY - 2007/01/12/received PY - 2007/07/12/accepted PY - 2007/12/19/pubmed PY - 2008/3/14/medline PY - 2007/12/19/entrez SP - 261 EP - 268 JF - Clinical and experimental nephrology JO - Clin Exp Nephrol VL - 11 IS - 4 N2 - Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD. SN - 1342-1751 UR - https://www.unboundmedicine.com/medline/citation/18085385/CKD_MBD:_impact_on_management_of_kidney_disease_ L2 - https://dx.doi.org/10.1007/s10157-007-0492-5 DB - PRIME DP - Unbound Medicine ER -